Celon Pharma (LTS:0RKX) Total Receivables: zł67.5 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKX Celon Pharma SA LTS:0RKX
48 GF Score
Price zł22.50
GF Value zł26.68
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Total Receivables?

Celon Pharma LTS:0RKX 48 Total Receivables is zł67.5 Mil as of Mar. 2026. GuruFocus rates LTS:0RKX with a GF Score™ of 48/100 and a GF Value™ of zł26.68. The stock has 3 warning signs investors should review.

Celon Pharma's Total Receivables for the quarter that ended in Mar. 2026 was zł67.5 Mil.

Celon Pharma Total Receivables Historical Data

* Premium members only.

The historical data trend for Celon Pharma's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma Total Receivables Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.25 32.73 45.28 0.00 0.00

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.00 45.02 54.38 0.00 67.45
LTS:0RKX
48GF Score
Celon Pharma SA LTS:0RKX
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of zł67.5 Mil mean?
Celon Pharma (LTS:0RKX) has a Total Receivables of zł67.5 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Celon Pharma and its competitors.
Is Celon Pharma's Total Receivables too high?
Celon Pharma's current Total Receivables is zł67.5 Mil. Overall, Celon Pharma has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Total Receivables compare to ZTS and UTHR?
Celon Pharma's Total Receivables of zł67.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Celon Pharma and its competitors. Celon Pharma's current Total Receivables is zł67.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (LTS:0RKX) has a current Total Receivables of zł67.5 Mil. The stock's GF Value™ is zł26.68, compared to a current price of zł22.50 — trading 15.7% below its estimated fair value. The current Total Receivables is zł67.5 Mil. Celon Pharma's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Celon Pharma (LTS:0RKX), the current Total Receivables is zł67.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celon Pharma (LTS:0RKX) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of zł22.50 is trading 15.7% below its estimated GF Value™ of zł26.68.

Key valuation signals for LTS:0RKX:

  • Total Receivables: zł67.5 Mil
  • GF Value™: zł26.68 vs. price of zł22.50 (15.7% below fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RKX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celon Pharma Business Description

Other Exchanges CLN:Poland8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
48GF Score

Get the complete analysis for LTS:0RKX

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł22.50
Price
zł26.68
GF Value